title: Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
abstract: BACKGROUND
  A prospectively randomized trial was performed to compare the efficacy and toxicity of two chemotherapeutic regimens widely used in advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  From January 1989 to March 1992, 196 patients with measurable disease were included in the trial. Ninety-three patients received mitomycin-vindesine-cisplatin (MVP) and 94 mitomycin-ifosfamide-cisplatin (MIP).
  
  
  RESULTS
  The objective response rate (complete plus partial remissions) was 28% (26/93 patients, 95% confidence interval 20%-40%) in the MVP arm and 30% (28/94 patients, 95% confidence interval 20.5%-40%) in the MIP arm. The median survival was 8.5 and 9 months, respectively. Neither the response rates nor the median survivals were significantly different. Grade III-IV leukopenia was more frequent with MVP (13% vs. 2% of the courses, p < 0.001), as well as grade I-II neurologic toxicity (30% vs. 6%, p < 0.001). In contrast, grade I-II anemia and grade I-II urologic toxicity were more frequent with MIP (7% vs. 25%, p < 0.001 and 1% vs. 11%, respectively).
  
  
  CONCLUSIONS
  Given the low efficacy of both schemes in the treatment of advanced NSCLC, their use cannot be recommended outside of clinical trials.
authors.affiliation: Dept. of Medical Oncology, Hospital La Paz, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: González Barón
authors.forename: J
authors.initials: J
authors.lastname: Feliu
authors.forename: E
authors.initials: E
authors.lastname: Espinosa
authors.forename: C
authors.initials: C
authors.lastname: García Girón
authors.forename: E
authors.initials: E
authors.lastname: Blanco
authors.forename: P
authors.initials: P
authors.lastname: Garrido
authors.forename: A
authors.initials: A
authors.lastname: Colmenarejo
authors.forename: A
authors.initials: A
authors.lastname: Ordóñez
authors.forename: A
authors.initials: A
authors.lastname: Moyano
authors.forename: I
authors.initials: I
authors.lastname: de la Gándara
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects; D011374:Progesterone / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D012074:Remission Induction; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D008937:Mitomycins; D011374:Progesterone; D016685:Mitomycin; D014747:Vinblastine; D002945:Cisplatin; D007069:Ifosfamide